Cesca Therapeutics (KOOL) and Misonix (MSON) Head to Head Contrast
Cesca Therapeutics (NASDAQ:KOOL) and Misonix (NASDAQ:MSON) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, profitability, earnings, dividends, institutional ownership, analyst recommendations and risk.
Institutional & Insider Ownership
3.1% of Cesca Therapeutics shares are held by institutional investors. Comparatively, 12.9% of Misonix shares are held by institutional investors. 15.7% of Cesca Therapeutics shares are held by insiders. Comparatively, 23.8% of Misonix shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
This table compares Cesca Therapeutics and Misonix’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings and Valuation
This table compares Cesca Therapeutics and Misonix’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Cesca Therapeutics||$14.52 million||0.52||-$21.22 million||($0.98)||-0.36|
|Misonix||$36.68 million||4.74||-$7.61 million||N/A||N/A|
Misonix has higher revenue and earnings than Cesca Therapeutics.
This is a breakdown of current ratings and target prices for Cesca Therapeutics and Misonix, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Cesca Therapeutics currently has a consensus target price of $1.50, indicating a potential upside of 328.57%. Misonix has a consensus target price of $26.00, indicating a potential upside of 41.07%. Given Cesca Therapeutics’ higher probable upside, equities research analysts clearly believe Cesca Therapeutics is more favorable than Misonix.
Volatility & Risk
Cesca Therapeutics has a beta of -0.96, meaning that its stock price is 196% less volatile than the S&P 500. Comparatively, Misonix has a beta of 0.29, meaning that its stock price is 71% less volatile than the S&P 500.
Misonix beats Cesca Therapeutics on 10 of the 11 factors compared between the two stocks.
About Cesca Therapeutics
Cesca Therapeutics Inc. develops, commercializes, and markets a range of automated technologies and products for cell-based therapeutics in the United States, China, rest of Asia, Europe, and internationally. The company develops automated blood and bone marrow processing systems that enable the separation, processing, and preservation of cell and tissue therapy products. It offers AutoXpress System, a proprietary automated device and companion sterile disposable for concentrating hematopoietic stem cells from cord blood; Point-of-CareXpress System, a proprietary automated device and companion sterile disposable for the isolation and concentration of hematopoietic stem cells from bone marrow; CAR-TXpress System, a suite of multi-component automated system that allows the automated manufacturing, expansion, and storage of cellular therapies for immuno-oncology; BioArchive System, an automated cryogenic device for single-cassette based cryo-storage of biological license applications products; and manual bag sets for use in the processing and cryogenic storage of cord blood. The company is also developing autologous stem cell-based therapies that address medical needs for applications in the vascular, cardiology, and orthopedic markets. In addition, it provides cell manufacturing and banking services. The company was formerly known as ThermoGenesis Corp. and changed its name to Cesca Therapeutics Inc. in February 2014. Cesca Therapeutics Inc. was founded in 1986 and is headquartered in Rancho Cordova, California. Cesca Therapeutics Inc. is a subsidiary of Boyalife (Hong Kong) Limited.
Misonix, Inc. is a medical device company, which engages in the design, development, manufacture and marketing of therapeutic ultrasonic medical devices. Its products include the bonescalpel cutting system, which is used for surgical procedures of the spine and on maxillofacial procedures; the sonastar surgical aspirator, which is used to emulsify and remove soft and hard tumors; the sonicone wound cleansing and debridement system, which offers tissue specific debridement and cleansing of wounds for effective removal of devitalized tissue and fibrin deposits while sparing viable cells. The company’s ultrasonic medical devices are used in the following surgeries: spine, neuro, orthopedic, wound debridement, cosmetic, laparoscopic, and medical applications. The company was founded by Howard Alliger in 1959 and is headquartered in Farmingdale, NY.
Receive News & Ratings for Cesca Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cesca Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.